FDA Advisers Convinced by Benefits of Geron's Imetelstat for Blood Disorder Drug
Thursday, 14 March 2024, 21:37
Overview
FDA advisers endorsed the benefits of Geron's imetelstat for treating blood disorders.
Key Points:
- Supportive Vote: 12-to-2 margin in favor of imetelstat's benefits.
- Risk Management: Emphasis on manageable risks and toxicities of the injectable drug.
- Targeted Treatment: Approval sought for transfusion-dependent anemia in myelodysplastic syndromes patients.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.